What is NuSkin Enterprises's EV / EBITDA?

NuSkin Enterprises (NUS) reported EV / EBITDA of 3.5× in Q1 2026.

What is the long-term trend for NuSkin Enterprises's EV / EBITDA?

Over 4 years (2020 to 2025), NuSkin Enterprises's EV / EBITDA has grown at a -14.4% compound annual growth rate (CAGR), from 8.5× to 4.6×.

What does EV / EBITDA mean?

Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.

NuSkin Enterprises NUS EV / EBITDA

EV / EBITDA at other companies

Nature's Sunshine ProductsNATR

8.5×+4.1×

Lifevantage CorporationLFVN

5.6×-5.1×

USANA Health SciencesUSNA

3.7×-2.0×

Estee Lauder Companies Inc.EL

25.6×—

HerbalifeHLF

5.3×0.0×

Solesence, Inc. Common StockSLSN

42.4×—

Other financials

Income statement

See full

Revenue$320.6M-12.0%

Gross profit$214.5M-13.2%

Operating income$4.0M+141%

Net income$1.8M-98.3%

EPS (diluted)$0.04-98.1%

Balance sheet

See full

Cash & equivalents$198.7M-2.5%

Total debt$303.6M-8.2%

Total equity$794.1M+5.3%

Total assets$1.4B-1.1%

Cash flow

See full

Operating cash flow-$3.9M-1,107%

CapEx$13.7M+1.0%

Free cash flow-$17.6M-33.6%

Valuation

See full

Market cap$256.35M-34.9%

Where this comes from

Calculated from NuSkin Enterprises’s reported figures.

enterprise value/ebitda=3.5×

Based on the most recent quarter.

The official record: NuSkin Enterprises’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about NuSkin Enterprises's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NuSkin Enterprises's EV / EBITDA?: NuSkin Enterprises (NUS) reported EV / EBITDA of 3.5× in Q1 2026.
What is the long-term trend for NuSkin Enterprises's EV / EBITDA?: Over 4 years (2020 to 2025), NuSkin Enterprises's EV / EBITDA has grown at a -14.4% compound annual growth rate (CAGR), from 8.5× to 4.6×.
What does EV / EBITDA mean?: Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.